Editorial: Enzalutamide withdrawal syndrome: is there a rationale?
Enzalutamide is a second generation non-steroidal antiandrogen (AA), which significantly improved overall survival (OS) and progression-free survival (PFS) after docetaxel (AFFIRM study), and OS and radiographic PFS before chemotherapy (PREVAIL study) in patients with metastatic castration-resistant prostate cancer (mCRPC) [1]. Being a potent androgen receptor (AR) antagonist, an enzalutamide withdrawal syndrome (EWS) appeared unlikely [2,3]. In contrast with this position, and considering […]